The invention relates to improved therapeutics for treating diseases or conditions that provide greater bioavailabilty and more predictable dosing. The invention relates to a chimeric protein comprised of a biologically active molecule linked to an Fc fragment of an immunoglobulin, wherein the chimeric protein binds less serum albumin compared to the same biologically active molecule of the chimeric protein not linked to an Fc fragment of an immunoglobulin. The invention also relates to a method of treating a disease or condition said method comprising administering a chimeric protein comprising a biologically active molecule linked to an Fc fragment of an immunoglobulin, wherein the chimeric protein binds less serum albumin compared to the same biologically active molecule of the chimeric protein not linked to an Fc fragment of an immunoglobulin